Market News & Trends
Genisphere Begins Collaborative & Sponsored Research Program With the University of Maryland
Genisphere LLC, provider of the 3DNA® drug delivery platform, has signed a collaborative and sponsored research agreement with the University of Maryland, through Dr. Silvia…
Pharmatek Adds Further cGMP Spray Drying Capacity in Response to Demand for Improved Pharmaceutical Solubility
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it…
Q BioMed Announces Licensing Agreement
Q BioMed Inc. (QBIO) and ASDERA LLC recently announced a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA's ASD-002, which is…
Q BioMed Announces Licensing Agreement
Q BioMed Inc. (QBIO) and ASDERA LLC recently announced a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA's ASD-002, which is…
GNT Biotech & Medicals Corporation to Begin Phase III Clinical Trial
GNT Biotech & Medicals Co., Ltd. recently announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen Biosciences Ltd., of Shenzhen, China,…
Sucampo Publishes Study Results for Treatment of Niemann-Pick Disease Type C1
Sucampo Pharmaceuticals, Inc. recently announced the publication of a new study in an independent scientific journal that confirms the unique composition of VTS-270, a 2-Hydroxypropyl-beta-cyclodextrin…
Protalix BioTherapeutics Announces New Preclinical Results
Protalix BioTherapeutics, Inc. recently announced new, promising results from a preclinical trial conducted in collaboration with Prof. Raphael Schiffmann, Director, Institute of Metabolic Disease at…
Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase III Study
Motif Bio plc recently announced positive topline results from REVIVE-1, a global Phase III clinical trial of its investigational drug candidate iclaprim in patients with…
Cobra Biologics Embarks on Gene Therapy Manufacturing Operations Expansion
Cobra Biologics, an international CDMO of biologics and pharmaceuticals, recently announced it is to expand operations at its sites in UK and Sweden to meet…
Cellectar Biosciences Receives Patent for CLR 131 & CLR 125 for the Treatment of Cancer Stem Cells
Cellectar Biosciences, Inc. recently announced the Japanese Patent Office has granted a method of use patent for two of the company’s phospholipid drug conjugates (PDCs),…
SteadyMed Raises $30 Million
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
SteadyMed Raises $30 Million
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to…
Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to…
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for patients with platinum-resistant ovarian cancer,…
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for patients with platinum-resistant ovarian cancer,…
Intellia Therapeutics Granted CRISPR/Cas9 Genome Editing Technology Patent
Intellia Therapeutics recently announced that the European Patent Office (EPO) has decided to grant a patent broadly covering the CRISPR/Cas9 genome editing technology. The patent…
Idera Pharmaceuticals Advances Investigational Treatment
Idera Pharmaceuticals, Inc. recently announced successful completion of the Phase I portion of the ongoing Phase I/II clinical trial of intratumoral IMO-2125. Intratumoral IMO-2125 is…
Nabriva Therapeutics Announces Enrollment Completion for Phase 3 Clinical Trial
Nabriva Therapeutics AG recently announced it has completed enrollment in its first lefamulin evaluation against pneumonia (LEAP 1) Phase 3 clinical trial. LEAP 1, which…
Lhasa & Optibrium Enter Research & Product Development Collaboration
Optibrium and Lhasa Limited recently announced they have formed a collaborative partnership to research next-generation drug metabolism modelling. Results from the work will be used…
